# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G**

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )

# Proteon Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

74371L109 (CUSIP Number)

September 25, 2018 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

☑ Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	New Leaf Biopharma Opportunities II, L.P. ("Biopharma II")				
2					
3	SEC USE Of	NI V			
3	SEC OSE O	NL I			
4	CITIZENSH	IP O	R PLACE OF ORGANIZATION		
	Delaware				
		5	SOLE VOTING POWER		
NUMBER OF			1,523,200 shares; except that (i) New Leaf BPO Associates II, L.P. ("NLBA II"), the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares; (ii) New Leaf BPO Management II, L.L.C. ("NLB Management II"), the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Ronald M. Hunt ("Hunt"), Vijay K. Lathi ("Lathi"), Liam T. Ratcliffe ("Ratcliffe"), and Isaac Manke ("Manke") the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
	SHARES		SHARED VOTING POWER		
	NEFICIALLY WNED BY				
	EACH		See response to row 5.		
R)	EPORTING	7	SOLE DISPOSITIVE POWER		
PERSON WITH			1,523,200 shares; except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of such shares.		
			SHARED DISPOSITIVE POWER		
			See response to row 7.		
9	AGGREGAT	E Al	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1.523,200 shares				
10	, ,		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	8.6%				
12	TYPE OF RE	EPOR	TING PERSON (SEE INSTRUCTIONS)		
	DNI				
	PN				

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Now, Loof DDO Associates H. L. D.				
2	New Leaf BPO Associates II, L.P.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
2		) <b>X</b>	TROTRIAL DOA II A WILMBER OF A GROOF (SEE INSTRUCTIONS)		
3	SEC USE Of	NLY			
4	CITIZENSH	IP OI	R PLACE OF ORGANIZATION		
	D 1				
	Delaware	5	SOLE VOTING POWER		
		3	SOLE VOTING POWER		
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
			be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate		
			general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi, Ratcliffe,		
<b>.</b>	n (DED OF		and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
	JMBER OF SHARES	6	SHARED VOTING POWER		
BENEFICIALLY			S		
OWNED BY		7	See response to row 5.  SOLE DISPOSITIVE POWER		
DI	EACH	,	SOLE DISTOSITIVE TO WER		
	EPORTING PERSON		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
	WITH		be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and		
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,		
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of		
		-	such shares.		
		8	SHARED DISPOSITIVE POWER		
			See response to row 7.		
9	AGGREGAT	E Al	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,523,200 shares				
10	CHECK IF T	HE A	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	TERCENT OF CERESTRESENTED DT INICONT ENROW (7)				
	8.6%				
12	TYPE OF RE	EPOR	TING PERSON (SEE INSTRUCTIONS)		
	PN				

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Now Loof Di	O M	Ianagement II, L.L.C.	
2			PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
2		EAP ) 🗷	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(a) 🗆 (b)	, 🖎		
	and then on			
3	SEC USE O	NLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
	Belaware	5	SOLE VOTING POWER	
		5	SOLL VOID TOWER	
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.	
	JMBER OF	6	SHARED VOTING POWER	
	SHARES			
	NEFICIALLY		See response to row 5.	
O	WNED BY EACH	7	SOLE DISPOSITIVE POWER	
DI	-			
REPORTING PERSON WITH			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of such shares.	
		8	SHARED DISPOSITIVE POWER	
			See response to row 7.	
9	AGGDEGAT	E Vi	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
9	AGGREGAT	LA	WOONT BENEFICIALLY OWNED BY EACH REFORTING LEASON	
	1,523,200 sh			
10	CHECK IF T	HE A	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT C	F CI	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	8.6%			
12	TYPE OF RE	EPOR	TING PERSON (SEE INSTRUCTIONS)	
	OO			

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Ronald M. F				
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) ☑				
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	United States citizen				
		5	SOLE VOTING POWER  See response to row 6.		
		6	SHARED VOTING POWER		
NUMBER OF SHARES BENEFICIALLY OWNED BY			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
RI	EACH EPORTING PERSON	7	SOLE DISPOSITIVE POWER  See response to row 8.		
	WITH	8	SHARED DISPOSITIVE POWER		
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of such shares.		
9	AGGREGAT	Έ Al	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,523,200 sh	ares			
10	CHECK IF T	HE A	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	8.6%				
12	TYPE OF RE	EPOR	TING PERSON (SEE INSTRUCTIONS)		
	IN				
II					

1	NAMES OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Vijay K. Lathi				
2		E AP ) ☑	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
	$(a) \sqcup (b)$	) 🗷			
2	SEC LISE OF	II 37			
3	SEC USE Of	NL Y			
4	CITIZENGII	ID O	D. DI. A OF OF OD CANIFFATION		
4	CITIZENSH	IP O	R PLACE OF ORGANIZATION		
	United State	a aiti	iron		
	United State	5	SOLE VOTING POWER		
		3	SOLE VOTING POWER		
			See response to row 6.		
		6	SHARED VOTING POWER		
		J	OTHER TOTAL OF THE		
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
	JMBER OF		be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate		
	SHARES		general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi, Ratcliffe,		
	NEFICIALLY WNED BY		and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
	EACH	7	SOLE DISPOSITIVE POWER		
R)	EPORTING				
	PERSON		See response to row 8.		
	WITH	8	SHARED DISPOSITIVE POWER		
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
			be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,		
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of		
			such shares.		
9	AGGREGAT	ΈAľ	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,523,200 sh				
10	CHECK IF T	HE A	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	8.6%				
12	TYPE OF RE	EPOR	RTING PERSON (SEE INSTRUCTIONS)		
	D.				
	IN				

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	I.K.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Liam T. Ratcliffe				
2					
	(a) □ (b)	) <b>X</b>			
3	SEC USE Of	NLY			
4	CITIZENSH	IP O	R PLACE OF ORGANIZATION		
	United State	s citi	izen		
	Omred State	5	SOLE VOTING POWER		
		-	See response to row 6.		
		6	SHARED VOTING POWER		
NII	DADED OF		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
	JMBER OF SHARES		be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate		
BEN	NEFICIALLY		general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
O	WNED BY EACH	7	SOLE DISPOSITIVE POWER		
R)	EPORTING				
	PERSON	8	See response to row 8.  SHARED DISPOSITIVE POWER		
	WITH	8	SHAKED DISPOSITIVE POWEK		
			1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
			be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and		
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt, Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of		
			such shares.		
9	AGGREGAT	E Al	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,523,200 shares				
10			AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT C	)F CI	LASS REPRESENTED BY AMOUNT IN ROW (9)		
	8.6%				
12	TYPE OF RE	EPOR	RTING PERSON (SEE INSTRUCTIONS)		
	INI				
	IN				

1	NAMES OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Isaac Manke	•			
2	CHECK TH	E AP	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
	(a) □ (b)	) <b>X</b>			
3	SEC USE Of	NLY			
4	CITIZENSH	TD ()	R PLACE OF ORGANIZATION		
7	CITIZENSII	11 0	RILACE OF ORGANIZATION		
	I I:4 - J C4-4-	:.			
	United State				
		5	SOLE VOTING POWER		
			See response to row 6.		
		6	SHARED VOTING POWER		
NII	JMBER OF		1,523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
	SHARES		be deemed to have sole power to vote such shares; (ii) NLB Management II, the sole general partner of NLBA II and ultimate		
	NEFICIALLY		general partner of Biopharma II, may be deemed to have sole power to vote such shares; and (iii) each of Hunt, Lathi, Ratcliffe,		
	WNED BY		and Manke, the managing directors of NLB Management II, may be deemed to have shared power to vote such shares.		
	EACH	7	SOLE DISPOSITIVE POWER		
R	EPORTING				
	PERSON		See response to row 8.		
	WITH	8	SHARED DISPOSITIVE POWER		
			1.523,200 shares, all of which are owned by Biopharma II; except that (i) NLBA II, the sole general partner of Biopharma II, may		
			be deemed to have sole power to dispose of such shares; (ii) NLB Management II, the sole general partner of NLBA II and		
			ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares; and (iii) each of Hunt,		
			Lathi, Ratcliffe, and Manke, the managing directors of NLB Management II, may be deemed to have shared power to dispose of		
			such shares.		
9	AGGREGAT	E A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,523,200 sh	ares			
10	, ,		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11		F CI	LASS REPRESENTED BY AMOUNT IN ROW (9)		
1.1	TERCEIVIC	<i>/</i> 1 C1	ELISS REIRESENTES STRENGON INNOW ()		
	8.6%				
1.2		DOF	OTING DED CON (CEE INCTDICTIONS)		
12	TYPEOFRE	CPOF	RTING PERSON (SEE INSTRUCTIONS)		
	D.				
	IN				

#### Schedule 13G

Item 1(a). Name of Issuer:

Proteon Therapeutics, Inc. (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

200 West Street Waltham, MA 02451

#### Item 2(a). Name of Persons Filing:

This joint statement on Schedule 13G is being filed by New Leaf Biopharma Opportunities II, L.P. ("Biopharma II"), New Leaf BPO Associates II, L.P. ("NLBA II") and New Leaf BPO Management II, L.L.C. ("NLB Management II" and together with Biopharma II and NLBA II, the "Reporting Entities") and Ronald M. Hunt ("Hunt"), Vijay K. Lathi ("Lathi"), Liam T. Ratcliffe ("Ratcliffe"), and Isaac Manke ("Manke" and, together with Hunt, Lathi, and Ratcliff, the "Managing Directors"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".

NLBA II is the sole general partner of Biopharma II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Biopharma II. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Biopharma II. Each of Hunt, Lathi, Ratcliffe and Manke are the managing directors of NLB Management II and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by Biopharma II.

## Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of Biopharma II, NLBA II, NLB Management II, Hunt, Ratcliffe and Manke is New Leaf Venture Partners, Times Square Tower, 7 Times Square, Suite 3502, New York, NY 10036.

The address of the principal business office of Lathi is New Leaf Venture Partners, 1200 Park Place, Suite 300, San Mateo, CA 94043.

## Item 2(c). Citizenship:

Each of Biopharma II and NLBA II is a limited partnership organized under the laws of the State of Delaware.

NLB Management II is a limited liability company organized under the laws of the State of Delaware.

Each Managing Director is a citizen of the United States.

## Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.001 par value per share ("Common Stock").

Item 2(e). <u>CUSIP Number</u>:

74371L109

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

## Item 4. Ownership.

(a) Amount beneficially owned:

See line 9 of cover sheets. Biopharma II is the record owner of the 1,523,200 shares of Common Stock (the "Biopharma II Shares"). As the sole general partner of Biopharma II, NLBA II may be deemed to own beneficially the Biopharma II Shares. As the sole general partner of NLBA II and ultimate general partner of Biopharma II, NLB Management II may be deemed to own beneficially the Biopharma II Shares. As the individual managing directors of NLB Management II, each of the Managing Directors also may be deemed to own beneficially the Biopharma II Shares.

### (b) Percent of class:

See Line 11 of cover sheets. The percentages set forth on the cover sheet for each Reporting Person are calculated based on 17,726,713 shares of Common Stock reported by the Issuer to be outstanding as of July 31, 2018 on Form 10-Q as filed with the Securities and Exchange Commission on August 7, 2018.

- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: see line 5 of cover sheets.
  - (ii) Shared power to vote or to direct the vote: see line 6 of cover sheets.
  - (iii) Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.
  - (iv) Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.

Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record and to the extent of their pecuniary interest therein.

#### Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

## Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Under certain circumstances set forth in the limited partnership agreements of each of Biopharma II and NLBA II, and the limited liability company agreement of NLB Management II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

Item 7. <u>Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

Item 10. <u>Certification</u>.

Not applicable.

Material to be Filed as Exhibits.

 $Exhibit \ 1-Agreement \ Regarding \ Joint \ Filing \ of \ Schedule \ 13G.$ 

## **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 6, 2018

NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

By: NEW LEAF BPO ASSOCIATES II, L.P. Its General Partner

By: NEW LEAF BPO MANAGEMENT II, L.L.C. Its General Partner

By: /s/ Craig L. Slutzkin
Craig L. Slutzkin
Chief Financial Officer

NEW LEAF BPO ASSOCIATES II, L.P.

By: NEW LEAF BPO MANAGEMENT II, L.L.C. Its General Partner

By: /s/ Craig L. Slutzkin
Craig L. Slutzkin
Chief Financial Officer

Isaac Manke

NEW LEAF BPO MANAGEMENT II, L.L.C.

By: /s/ Craig L. Slutzkin
Craig L. Slutzkin
Chief Financial Officer

\*
Vijay K. Lathi

\*
Ronald M. Hunt

\*
Liam T. Ratcliffe

/s/ Craig L. Slutzkin

\* Craig L. Slutzkin As attorney-in-fact

\* This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.

## AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Proteon Therapeutics, Inc.

Date: November 6, 2018					
NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.					
By: NEW LEAF BPO ASSOCIATES II, L.P. Its General Partner					
By: NEW LEAF BPO MANAGEMENT II, L.L.C. Its General Partner					
By: /s/ Craig L. Slutzkin Craig L. Slutzkin Chief Financial Officer					
NEW LEAF BPO ASSOCIATES II, L.P.					
By: NEW LEAF BPO MANAGEMENT II, L.L.C. Its General Partner					
By: /s/ Craig L. Slutzkin					
Craig L. Slutzkin Chief Financial Officer					
NEW LEAF BPO MANAGEMENT II, L.L.C.					
By: /s/ Craig L. Slutzkin					
Craig L. Slutzkin					
Chief Financial Officer					
*					
Vijay K. Lathi					
*					
Ronald M. Hunt					
*					
Liam T. Ratcliffe					
*					

Isaac Manke

/s/ Craig L. Slutzkin

Craig L. Slutzkin As attorney-in-fact

\* This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.